Patients flocked to those Ozempic, Wegovy copycats when the branded drugs were in short supply, or if they didn’t have ...

The trial met its primary objectives, showing the pill’s effectiveness in helping patients with Type 2 diabetes achieve ...

I n an hour-long meeting at Eli Lilly and Company’s headquarters in Indianapolis on April 15, the pharmaceutical company’s top executives met, like they had dozens of times before, to hear the ...

HIMS has experienced similar dramatic drops before. During the 2022 inflation surge, the stock fell 87%, and in 2020, it ...

We recently published a list of 10 Best Pharma Stocks to Buy for Long Term Growth. In this article, we are going to take a ...

European equities are heading for a sharply higher open, with investors still reeling from one of the wildest weeks for ...

Today's Research Daily features new research reports on 16 major stocks, including The Procter & Gamble Co. (PG), Novo Nordisk A/S (NVO) and PepsiCo, Inc. (PEP), as well as two micro-cap stocks ...

In this exclusive interview, Business Today speaks with Vikrant Shrotriya, Managing Director of Novo Nordisk India, about the significance of semaglutide (the active ingredient in Wegovy), its ...

Novo Nordisk is preparing to launch its blockbuster obesity drug Wegovy (injectable semaglutide) in India later this year, the company told Business Today, setting the stage for a high-stakes ...

It has been a tough period for Novo Nordisk shareholders. In the summer of 2024 ... Yesterday, the Danish Prime Minister, Mette Frederiksen, wrote a letter of condolence for the death of Pope Francis.

While much of the recent GLP-1 saga has been written in the U.S., Novo Nordisk continues to expand its semaglutide empire across the globe and make inroads into large markets like Brazil.